Jon Amund Kyte

17PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCheminformatics and quantitative structure-activity relationshipsTumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 20, 2026
Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.

|Aug 25, 2025
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy.

Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen

|Jun 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.

Andreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde

|Dec 20, 2024
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival.

Ragnhild Reehorst Lereim, Claire Dunn, Elin Aamdal

|Nov 15, 2024
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold

|Sep 28, 2024
Correction: Jin et al. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Int. J. Mol. Sci. 2024, 25, 586.

Yixin Jin, Claire Dunn, Irene Persiconi

Pageof 3

Frequent Collaborators

6 joint publications

Andreas Hagen Røssevold

6 joint publications

Nikolai Kragøe Andresen

4 joint publications

Bjørn Naume

3 joint publications

Carole Beck